Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Nadav Ofshenko, Eyal Bercovich, Tania Mashiach, Michal Weiler-Sagie, Daniela Militianu, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 4042.

https://doi.org/10.1182/blood-2019-122675

Published: 2019

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Journal Articles

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Martha Hernandez-Illas, Tong Lin, Andres Rey, Jack Jenkins, Reddy Chandula, Mi Rim Choi, MD

Blood (2019) 134 (Supplement_1): 3817.

https://doi.org/10.1182/blood-2019-123695

Published: 2019

Journal Articles

Decitabine As First Line Treatment in Acute Myeloid Leukemia of the Elderly: Real-Life Experience from a Single Center

Eleni Bouronikou, Eleni Georgiadi, George Vassilopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5137.

https://doi.org/10.1182/blood-2019-123028

Published: 2019

Journal Articles

Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System

John Khoury, MD, Nwabundo Anusim, MD, David Macari, MD, Angela Duenn, PharmD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 5117.

https://doi.org/10.1182/blood-2019-130776

Published: 2019

Journal Articles

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Mohamed A Yassin, MBBS, MSc, Mohammad Abdul-Jaber Abdulla, MD, Feryal Abbas, MD PhD, Prem Chandra, PhD, Abdulqadir Jeprel Nashwan, BSN, MSN, Rola S Ghasoub, BSC, Nancy Kassem, BSC, Ahmad Al Sabbagh, MD, Zafar Nawaz, PhD, Susanna Jane Akiki, PhD

Blood (2019) 134 (Supplement_1): 5912.

https://doi.org/10.1182/blood-2019-125700

Published: 2019

Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume

Blood (2019) 134 (Supplement_1): 3362.

https://doi.org/10.1182/blood-2019-124934

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Key Histopathology Features of Cutaneous Acute Graft-Versus-Host Disease Can be Detected Noninvasively

Inga Saknite, PhD, Melissa Gill, MD, Alessi-Fox Christi, MS, Jeffrey P Zwerner, MD PhD, Julia S Lehman, MD, Michi M Shinohara, MD, Roberto A Novoa, MD, Michael T Byrne, DO, Madan Jagasia, MBBS, MS, MMHC, Salvador Gonzalez, MD PhD, Marco Ardigo, MD PhD, Eric R. Tkaczyk, MD PhD

Blood (2019) 134 (Supplement_1): 3278.

https://doi.org/10.1182/blood-2019-131317

Published: 2019

Journal Articles

Identifying ARHGEF12 As an Important Regulator of Erythropoiesis By Calculating Red Blood Cell Transfusion for Chemotherapy Induced Anemia and By Conditional Knockout Mouse Model

Yangyang Xie, Ruichi Wu, Li Gao, MD, Xiaoxiao Chen, Xiao-Jian Sun, PhD, Shuhong Shen, MD PhD

Blood (2018) 132 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2018-99-117724

Published: 2018

Journal Articles

Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Blood (2018) 132 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2018-99-119566

Published: 2018

Journal Articles

Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies

Blood (2018) 132 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2018-99-110980

Published: 2018

Journal Articles

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Evangelos Terpos, MD PhD, Maria Roussou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Despina Fotiou, MD, Dimitrios C. Ziogas, MD, Aristea-Maria Papanota, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Efstathios Kastritis, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2018-99-113108

Published: 2018

Journal Articles

Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients

Elizabeth A Lakota, PharmD, MS, Shawn Flanagan, PhD, Taylor Sandison, MD, MPH, Janice W Brown, MD, Christopher M Rubino, Pharm.D.

Blood (2018) 132 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2018-99-110300

Published: 2018

Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli

Blood (2018) 132 (Supplement 1): 783.

https://doi.org/10.1182/blood-2018-99-116845

Published: 2018

Journal Articles

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Blood (2018) 132 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2018-99-113257

Published: 2018

Journal Articles

One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

James K McCloskey, MD, Genique Stanislaus, ANP, Yen-Hong Kuo, PhD, Jamie Koprivnikar, MD

Blood (2018) 132 (Supplement 1): 5448.

https://doi.org/10.1182/blood-2018-99-119971

Published: 2018

Journal Articles

Induced Myelosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups

Dirk Pleimes, MD, Volker Möbus, Frank Mayer, Marcus Schmidt, Corinna Asang, Kathrin Flunkert, Gerd Mikus

Blood (2018) 132 (Supplement 1): 5106.

https://doi.org/10.1182/blood-2018-99-114220

Published: 2018

Journal Articles

Recombinant VWF for Delivery in Women with Von Willebrand Disease

Nicoletta Machin, DO, Margaret V. Ragni, MD MPH

Blood (2018) 132 (Supplement 1): 2469.

https://doi.org/10.1182/blood-2018-99-111536

Published: 2018

NARROW

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults

Decitabine As First Line Treatment in Acute Myeloid Leukemia of the Elderly: Real-Life Experience from a Single Center

Outcome of Patients with Newly-Diagnosed Therapy-Related AML (t-AML) and AML with Myelodysplasia-Related Changes (AML-MRC) Treated with Liposomal Daunorubicin and Cytarabine (CPX-351) at an Academic Community-Based Health System

Clinico-Pathological Profiles of Obese Patients with Chronic Myeloid Leukemia (CML) and Their Response to Therapies (TKIs)

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Key Histopathology Features of Cutaneous Acute Graft-Versus-Host Disease Can be Detected Noninvasively

Identifying ARHGEF12 As an Important Regulator of Erythropoiesis By Calculating Red Blood Cell Transfusion for Chemotherapy Induced Anemia and By Conditional Knockout Mouse Model

Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)

Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

One Size May Not Fit All for TKI Dosing in Chronic Phase CML—Deep Molecular Responses Despite Dose Reduction

Induced Myelosuppression and Recommendation for Monitoring of Absolute Neutrophil Counts in Patients Treated with Epirubicin and Cyclophosphamide in Early Breast Cancer: Results from a Phase 2a Collaborative Trial of the AGO-B and CESAR Study Groups

Recombinant VWF for Delivery in Women with Von Willebrand Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only